4.5 Article

Efficacy of transauricular vagus nerve stimulation for the treatment of chemotherapy-induced painful peripheral neuropathy: a randomized controlled exploratory study

Journal

NEUROLOGICAL SCIENCES
Volume -, Issue -, Pages -

Publisher

SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s10072-023-07229-2

Keywords

Transauricular vagus nerve stimulation (taVNS); Chemotherapy-induced peripheral neuropathy (CIPN); Vagus nerve stimulation (VNS)

Ask authors/readers for more resources

Transauricular vagal nerve stimulation (taVNS) can effectively relieve chemotherapy-induced neuropathic pain in the short term, improve sleep status and quality of life in patients with CIPN, and is expected to become a novel clinical treatment method. However, the mechanism of taVNS in CIPN needs further investigation.
BackgroundChemotherapy-induced painful peripheral neuropathy (CIPN) is a common adverse event in cancer patients, and there is still a lack of effective treatment. Transauricular vagal nerve stimulation (taVNS) is a minimally invasive treatment, but there are few reports regarding its efficacy for CIPN.ObjectiveTo investigate the efficacy and possible mechanism of taVNS in patients with CIPN.MethodsTwenty-seven patients with CIPN were randomly divided into a taVNS group (n = 14) and a sham stimulation (SS) group (n = 13). A numerical rating scale (NRS) for pain, NCICTCAE 4.0 (neurotoxicity classification), quantitative sensory test (QST), Short-Form-Health Survey-12 (SF-12), and Athens Insomnia Scale (AIS) were administered before the intervention (D-10) and on the day after the intervention (D0), and the inflammatory cytokines in plasma were also measured. The NRS, NCI-CTCAE 4.0, SF-12, and AIS were administered again at D30 and D90.ResultsCompared with the SS group, the NRS and AIS in the taVNS group were significantly lower at D0. The impact lasted until D30. There were no statistically significant differences in the NRS and AIS between the 2 groups at D90. On D30, the mental component score of the SF-12 was significantly higher in the taVNS group than in the SS group. No adverse events were found. There was no significant difference in QST and plasma inflammatory cytokines between the 2 groups.ConclusiontaVNS can relieve chemotherapy-induced neuropathic pain in the short term, can improve sleep status and quality of life, and is expected to become a novel clinical treatment method for CIPN.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available